Eledon Pharmaceuticals, Inc. reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart in patients undergoing kidney transplantation at the World Congress of Nephrology, which is taking place March 30 to April 2, 2023. In addition, Eledon reported safety data from the Company's Phase 2a trial of tegoprubart in IgA Nephropathy. The Phase 1b open-label study is enrolling up to 12 participants undergoing kidney transplantation in Canada, Australia, and the United Kingdom.

Each participant receives rabbit antithymocyte globulin induction and a maintenance regimen consisting of tegoprubart 20 mg/kg IV (administered every 3 weeks after an initial loading regimen), mycophenolate mofetil, and corticosteroids. The primary endpoint of the study is safety. Other endpoints include characterizing the pharmacokinetic profile of tegoprubart, the incidence of biopsy proven rejection, changes in estimated glomerular filtration rate, and exploratory biomarkers including donor derived cell free DNA.

Results from the first three participants at the time of data submission to the conference demonstrated no incidence of acute rejection at 56, 167, and 232 days.